Diabetes Management

Part
01
of nine
Part
01

Diabetes Management Products: Trends, Part 1

Two of the trends around diabetes management products in the US are the growing uptake of continuous glucose monitoring and innovations in automated insulin delivery.

Continuous Glucose Monitoring (CGM)

  • Continuous glucose monitoring systems are considered essential for the treatment of insulin-dependent diabetes. They are supposed to bring better long-term outcomes thanks to monitoring glucose levels in real-time, which allows for making better short-term decisions. Due to recent regulatory changes and more innovative products coming to the market, the CGM technology uptake is growing.
  • The emergence of continuous glucose monitoring systems has fueled the growth of the whole US diabetes monitoring market.
  • According to Market Reports World, continuous glucose monitoring is one of the key trends in the North American blood glucose monitoring market. It is the best tool to achieve glycemic balance and avoid hypoglycemia for patients using insulin pumps or multiple daily injections therapy.

Insights

  • In 2018, the FDA added a new category, "integrated continuous glucose monitoring systems," which makes it easier to bring CGM-related innovations to the market.
  • In late 2017, around 24% of patients with documented type 1 diabetes used CGM devices. However, the percentage has and will be growing with technological advancements and "broadening of inclusion criteria."
  • The United States accounts for the largest share of the North American $1.12 billion CGM market.
  • While the 2019 share is not available, in 2018, it was 97.44%.
  • The country is expected to maintain its dominance due to the highest prevalence of diabetes and good conditions for adapting new technologies.
  • The CGM market is expected to grow by 27.18% in the US until 2025, compared to 8.45% in the entire North America.

Company at the Forefront

  • DexCom, a San Diego-based company focused on innovative CGM systems, is at the forefront of the trend.
  • Its G5 Mobile CGM Systems were the first that the FDA approved for "making diabetes treatment decisions without the need for a confirmatory blood glucose measurement," while their G6 was the first in the new CGM-related medical device category created by the FDA.

Automated Insulin Delivery (AID)

  • According to experts from DiabetesMine's 2019 Innovation Summit, 2020 will be the year of automated insulin delivery (AID), also known as Bionic Pancreas, artificial pancreas, hybrid closed loop, and predictive low glucose suspend. It involves an algorithm and a monitoring device that adjusts an insulin dose and delivers it via a pump.
  • Also, developments in AID, such as DexCom's acquisition of TypeZero Technologies and the FDA approval of AID device by Tandem Diabetes Care, were included among key news in reports on the diabetes management devices market.

Insights

  • Currently, only three AID solutions are available in the US market — Medtronic MiniMed 670G, Tandem Basal-IQ, and Tandem Control-IQ. In 2020, between three and five products from this category will be launched.
  • Until 2020, the AID devices that are in the market are capable of stopping or reducing insulin delivery when glucose is low, and "adjust basal insulin delivery depending on whether the user’s glucose is trending up or down." With the launch of Tandem Control-IQ, they will also deliver correction boluses.
  • The global artificial pancreas device system market is expected to grow at a CAGR of 15.5%. While the US-specific growth predictions are not available, it is the largest region and will be the fastest-growing one.
  • Therefore, it accounts for the largest share of the $126.8 million artificial pancreas market (the figure includes Europe and North America), which will grow to $320.2 million in 2027.
  • The drivers of this trend include high competition between key players to bring innovative products to the market, as well as favorable market conditions in the US, which include good reimbursement policies and easy uptake of emerging technologies.
  • In 2019, Diabeloop raised $34 million in Series B to finance the deployment of its AID system. In 2020, Bigfoot Biomedical raised $45 million in Series C to finance the development of its digital insulin-dosing platform.

Company at the Forefront

  • Tandem Diabetes Care is one of the companies at the forefront of the trend.
  • It is San Diego-based and solely dedicated to developing diabetes solutions.
  • One of its AID systems, Tandem Basal-IQ, was approved by the FDA in December 2019.
  • A more advanced system, Tandem Control-IQ, launched at the beginning of this year. It is the first one to provide correction boluses.

Research Strategy

Trends were selected based on being included in multiple reports on the diabetes devices and diabetes monitoring industries, and being mentioned in expert articles.
Part
02
of nine
Part
02

Diabetes Management Products: Trends, Part 2

Two additional trends around diabetes management products are diabetes apps and artificial intelligence. Details about these trends have been provided below.

Diabetes Apps

  • Diabetes apps have becoming increasingly popular. The apps are ubiquitous and allow users to import glucose meter readings through plug-solutions or Bluetooth.
  • The use of diabetes apps has primarily been driven by the fact that they simplify the lives of people with diabetes. They enable people with diabetes to log their data, monitor trends, set objectives, and track progress.
  • Approximately 33% of individuals with type 2 diabetes and 52% with type 1 diabetes use apps to manage their conditions. Continuous glucose monitoring apps are popular among people with type 1 diabetes.
  • MySugr is an app that is leading this trend. The app enables users to track medicine, meals, and carbohydrate intake. The app is compatible with the Apple Health app, which enables it to collect step and physical activity data points.

Artificial Intelligence

  • The application of artificial intelligence in diabetes management products has been increasing rapidly. A good deal of health care companies are now using artificial intelligence in their solutions. Examples of products that are AI-powered include retinal imaging systems, insulin pumps, glucose sensors, and smartphone applications.
  • The growth of AI is attributed to the huge pool of available data and the intelligent methodologies that have the capability of processing this information. These two factors have led to the development of applications and tools that can improve the effective management of diabetes. In addition, AI applications offer greater efficiency, accuracy, and ease of use of diabetes management products.
  • A survey conducted in 2017 revealed that “68% of mobile app developers” hold the view that diabetes is one of the most promising health care markets when it comes to digital health solutions. The study notes that 61% of the developers view artificial intelligence as one of the most disruptive technologies in the digital health sector.
  • An example of a company that is leading this trend is Bigfoot Biomedical, a diabetes management company based in California. The company is developing an AI-driven automated insulin delivery that has an artificial pancreas. The startup leveraged on AI to develop a closed-loop system that can monitor and learn a user’s response to insulin, exercise, and food, and make the necessary dosage adjustments.

Research Strategy

To find the requested information, we looked through research databases and industry sites, such as NCBI, Health Analytics, and HIT Consultant. We then selected two trends that were mentioned the most from these sources.
Part
03
of nine
Part
03

Diabetes Self-Management: Trends, Part 1

As diabetes remains a prevalent condition both in the U.S. and globally, efforts to improve patient outcomes have skyrocketed. According to the American Diabetes Association (ADA), the cost of diagnosed diabetes has risen to $327 billion. With emerging health trends and technologies, however, patients are now becoming more empowered to take control of their health through self-management strategies.

Low-Carbohydrate Diets

  • Patient consumers are starting to adhere to diets with reduced carbohydrates, grains, and sugar in favor of more vegetables, fat, and meat. According to a poll of 1,259 registered dietitians conducted by marketing and PR agency Pollock Communications and Today’s Dietitian, the high fat, moderate protein, and ultra-low carb keto diet is likely to remain one of the top diet trends of 2020. Obesity rates, weight loss, and the increase in health-related issues such as diabetes are the driving factors behind this dietary trend.
  • Recent studies have shown that low-carb ketogenic diets may play a role in improving glycemic control. Reducing carbohydrate intake and eating foods with low glycemic index has been shown to be beneficial for diabetics. One randomized clinical control trial found that a diet low in carbohydrates resulted in improvements in blood glucose variability and reduction of diabetes medications. The study evaluated 115 obese patients with type 2 diabetes for 52 weeks.
  • Virta Health is a company promoting the ketogenic diet to improve and reverse type 2 diabetes. They provide remote medical care via an app-based system and create a customized nutrition plan for those with type 2 diabetes. The plan is based on recommendations from expert physicians and endorsed by the ADA.

Cost-Related Medication Adherence

  • Many patients with diabetes are not taking their medications as prescribed due to high costs. Adults under the age of 65 are more likely to not take their medication as prescribed and tend to inquire about lower-cost medications from their doctor, according to a 2019 NCHS Data Brief released by the CDC.
  • One recent study from JAMA Internal Medicine found that the increase in insulin prices may be fueling cost-related adherence to insulin. Out of 354 subjects, 25% of them reported insulin underuse. Many of these patients experienced poor glycemic control which is prompting action to improve medication affordability.
  • Prescription discount companies like GoodRx aim to improve access to medications and reduce cost-related nonadherence. SingleCare also uses a drug search engine to find prescription cost savings based on location, pharmacy, and generic availability. While these companies focus on cost-related problems, other companies are looking at ways to improve medication adherence through personal glucose monitoring systems as well as coaching and educational programs.

Part
04
of nine
Part
04

Diabetes Self-Management: Trends, Part 2

Two trends around diabetes self-management in the US are the use of yoga classes to maintain fitness and manage symptoms, and following the Mediterranean diet.

Diabetes and Yoga

  • Increasingly yoga has become a form of exercise praised for its ability to help manage diabetes with substantial research carried out into its benefits.
  • Researchers have discovered that certain postures provide direct stimulation of the pancreas, rejuvenating its capacity to produce insulin. Research has also found that those who regularly practice yoga experience improvement in fasting glucose and cholesterol levels.
  • The number of Americans using yoga for health and well-being increased by 55% in 2019 with more than 35 million Americans favoring it over pharmaceutical treatments. One in three Americans have tried yoga at least once with 10% of US adults using yoga as a complimentary health approach.
  • 40% of those doing yoga report healthier eating habits and many diabetics who practice yoga report a decrease in stress and increase in weight loss and general fitness. Recent research confirms that a lower BMI decreases the mortality rate among diabetic sufferers.
  • The health and well-being benefits are the driving force behind the growing trend with many providers developing specific yoga programs for diabetics.
  • There are an estimated 6,000 yoga centers in the US with many offering diabetic friendly programs.

Practitioner at the Forefront

  • Yoga for Diabetics is a book written by Rachel Zinman as a guide and encouragement to those who wish to try yoga in the treatment of their diabetes. The book has received 5 star reviews on Amazon.
  • Rachel Zinman's blog has had industry recognition and she is recognized as one of 8 social media influencers making an impact in her field.
  • Her articles on yoga and diabetes have been featured in print magazines and online on sites such as mindbodygreen, Beyond Type 1, OnTrack Diabetes, Insulin Nation and Diabetes Daily.

Mediterranean Diet

  • For the third year in a row the diet has been named the best diet in the US and is the number 1 recommended diet for diabetics by the U.S. News & World Report annual rankings.
  • The diet contains heart healthy unsaturated fats, fiber and fish which aid diabetics in improving blood glucose levels, cardiovascular health and cholesterol levels. Research shows diabetics following a Mediterranean diet saw a drop in their A1C levels.
  • Research suggests the Mediterranean diet may prevent the onset of diabetes by 52%.
  • The diet was particularly popular on the West Coast and Northeast of America in 2018 when researched surveyed 21,000 non-Hispanic adults across 48 states with nearly 50% reportedly following the diet, with the trend expected to grow.
  • 5 research studies on those with metabolic conditions such as diabetes showed the diet helped 13.7% of patients reverse the effects of diabetes, helped to reduce insulin resistance, improved blood glucose and insulin levels, and showed that the diet could help prevent the need for medication in newly diagnosed patients.

Company at the Forefront

  • My Diabetes.diet offer tailor made meal plans for those with diabetes. These include plans based on the Mediterranean diet.
  • There is a cost to access the plan, and users are required to enter some personal information and answer a simple survey.
  • Although the plans offered by mydiabetes.diet are tailored to each individual, many online blogs and websites offer meal plans that follow the same diet free of charge. These include diabetes.org, eatingwell.com and healthline.com.

Research Strategy

To find information on self management tools we used medical journals and expert industry sites such as the ADA, NCBI, CDC and Health Analytic. Trends were then selected based on them being included in many of these sources and having had significant credible research carried out into their effectiveness.
Part
05
of nine
Part
05

Diabetes Self-Management: Consumer Attitudes

Diabetic patients' perception of their skills and knowledge influences their willingness to adhere to treatment and lifestyle changes. Americans are confident they can self-manage their diabetes, but are less healthy and less likely to follow directions regarding insulin and medication properly.

Diabetes Self-management

  • Diabetic patients describe managing their condition as challenging, depressing, confusing, scary, and frustrating. Most crave help to manage the stress associated with the condition (32%) and desire emotional support (30%), while others need help with everyday tasks, such as food preparation (23%) and household chores (22%). Nevertheless, nearly 38% manage the condition by themselves, without the help of friends or family.
  • Technical tasks can also be challenging. Seventy-five percent reported checking their blood glucose at least once a day; however, only 54% were confident they were checking it correctly and at the right time.
  • One of the most critical aspects of self-managing diabetes is the patients’ lifestyle. Unfortunately, data from the CDC shows that 89% of U.S. adults diagnosed with diabetes are overweight or obese, albeit 77% claim they are managing or losing weight to lower their risk. Nonetheless, only 24.4% actually meet the recommended 150 minutes per week of physical activity.
  • Seventy-eight percent reported having at least one usual health professional that cares for their diabetes. When asked what they discuss with their health providers, 59% said goals in managing diabetes, 59% said how and when to take medication, 58% said exercise routines, and 55% discussed diets and healthy eating.
  • Patients surveyed said they have tried to make lifestyle changes after the diagnosis, such as reducing sugar intake (81%), taking the medication regularly (79%), managing carbohydrates ingestion (69%), and exercising more (51%). Patients mentioned food cravings, exercising, and eating healthy outside of their homes as the biggest obstacles to manage their condition.

Ethnic Variances

  • According to the CDC, as of 2018, 8.2% of the U.S. population had diagnosed diabetes. Prevalence is higher among Hispanics (12.5%), followed by African Americans (11.7%), Asians (9.2%) and Non-Hispanic Whites (7.5%).
  • Researchers interviewed over 1,000 Americans with diabetes to discover if there are differences between how the different ethnic groups manage and perceive the condition. It discovered that insulin adherence is higher among Non-Hispanic Whites and Hispanics than African Americans and Chinese Americans.
  • African Americans monitored their blood glucose and conducted foot examinations more frequently than other cohorts, while Chinese Americans are more likely to adhere to a healthy diet. Non-Hispanic Whites are the least likely to exercise frequently.
  • When asked what self-management behavior they want to improve, all cohorts mentioned diet and physical activity as priorities (73% and 69% respectively).

Americans are Less Healthy and More Confident than Other Nationalities

  • A study compared type 2 diabetic patients in the U.S., Canada, UK, Germany, Spain, and Mexico to discover their health conditions and opinions. American patients were more likely to be overweight or obese (81%), to have high blood pressure (75%), high cholesterol (67%), neuropathy (44%), and heart diseases (16%) than patients from other countries, which could indicate Americans are not properly adhering to their treatments.
  • Fifty-three percent believe their diabetes is fairly well controlled; however, 33% expect complications within the next five years. Only 19% stated that they do not expect any future complications, a score lower than the other countries, except Canada.
  • Seventy percent said they never missed medical appointments regarding their diabetes. When asked what they to do to self-manage the disease, 86% said they exercised, 85% said they changed their diets to control the disease, 71% said they take tablets or pills for diabetes, 39% take insulin, and 16% take injectable medication other than insulin.
  • Insulin and medication adherence are lower in the U.S. than in other countries, with 86% saying they take pills and tablets as directed by their healthcare providers, and 70% saying they always take their insulin as directed by the provider. For reference, all the other countries, except Mexico, had percentages higher than 85% for both categories.
  • Nonetheless, Americans are more confident they can self-manage their diabetes than other countries. Fifty-five percent believe they can avoid serious problems due to low blood sugar when they are alone. They are also less worried, with 83% disagreeing with the statement, “I spend so much time worrying about the possibility of a low blood sugar episode that it interferes with my ability to do the things I really want to do.”

Factors Impacting Patients’ Skills and Ability to Manage Diabetes

  • Many factors impact patients’ ability and confidence concerning their self-management skills and decisions. Effective communication with health care providers, when there is trust, respect and shared decision-making, was correlated with the determination to engage in self-management, as well as strong social support from friends and family. The use of technology and higher income and educational levels further impact how patients deal with the disease.
  • Notably, how patients perceive their skills and efficacy to manage their condition dramatically changes their drive to engage in self-management activities. When patients are skeptical that their actions can achieve the desired effects, there is little incentive to act in the first place, regardless of other enabling factors.
  • A study conducted with over 200 patients in Europe, Australia and the United States examined how patients perceive their self-management skills, the barriers they face, and what enables them to continue. Patients reported being confident in their ability to recognize the effect of physical activity or carbohydrate consumption and handle the effects, as well as their skills to reduce risk by monitoring complications and using blood glucose to plan for meal intake.
  • The lowest scores were regarding identifying, managing and coping with the impact of stress on diabetes, adjusting medications for food intake to reach targeted blood glucose levels, planning exercises to avoid hypoglycemia, and interpreting blood glucose patterns.
  • Researchers found that two factors positively influenced self-management across all groups: the patient’s determination to prevent complications and willingness to adhere to treatment, and the use of technology. The most commonly mentioned technological supports were apps, insulin pumps, and continuous glucose monitors (CGM).
  • Patients use Apps to monitor and store data to create a self-management strategy for glycemic control. They also found reminder features useful to improve medication-taking behavior. Apps serve as motivation as well, as patients stated that when they are going through fluctuations and difficulties, looking at the data stored that showed proper levels offers assurance that their glucose levels will not always be unstable.
  • Insulin pumps and CGMs make it easier for patients to manage and monitor their diabetes. Insulin pumps also provide support and relief from pains experienced while using needles.

Barriers

  • The most common pain point reported by patients is the dynamic and chronic nature of the disease requiring multiple needs. The burden of relentless management results in "sub-optimal diabetes management and compromised quality of life."
  • They feel the disease is affected by various reasons, including environmental conditions, which leads to a constant need to adjust their self-management. The unstable nature of diabetes is also challenging, as patients noted that similar behavior impacts their health differently at distinct times.
  • The never-ending need for self-management discourages patients from adhering to treatment. They are sometimes unwilling to undertake their self-management because they know it is not a cure, so it often feels pointless.
  • Advice and unrealistic expectation from family and friends irritate patients and sometimes becomes a hindrance to self-management. Patients expressed frustration with constant surveillance and ignorant questions.
  • Furthermore, a lack of effective communication between patients and health professionals is another barrier. Patients do not necessarily agree with the recommendation from doctors and other health professionals. There is a discrepancy between what patients and professionals believe should constitute patient care and self-management.
Part
06
of nine
Part
06

Diabetes Management Products Companies, Part 1

Becton Dickinson (BD) and DexCom highlight diabetes management within their core business models. However, Baxter focuses on 6 core areas of care, and does not explicitly call out diabetes management within its services or financial reporting. Each company has a unique competitive advantage within their target markets. Research findings have been presented on columns C-E, rows 3-8 of the attached spreadsheet.

Becton Dickinson

Baxter

  • Baxter released Myxredlin, the first and only ready-to-use Insulin for IV Infusion. This provides a competitive advantage in which Baxter is the only supplier within the space.
  • Baxter International Foundation to award $750,000 in funding to health centers and free and charitable clinics that are working to improve diabetes health outcomes for patients, focusing on the Greater Chicago Area.

DexCom

  • Dexcom G6 CGM System eliminates finger sticks and enhances patient knowledge through innovation.
  • The company partnered with Eli Lilly to integrate CGM platform into personalized Diabetes Management System.
  • Over the past 12 months, DexCom's revenue has risen by 42% to $1.47 billion.
Part
07
of nine
Part
07

Diabetes Management Products Companies, Part 2

Abbot and One Drop companies offer products and services for diabetes management. As explained in the spreadsheet, the two companies differ in a number of ways which include when they were founded, their products and services, their competitive advantage, and their target market.

ABBOT

  • Abbot specializes in medical devices, branded generic pharmaceuticals, diagnostics as well as nutrition products. The company has approximately 107,000 employees and serves over 160 countries across the world.
  • It was founded in 1888 by Dr. Wallace C. Abbot, a drug store proprietor. Therefore, to date, the company has been actively operational for 132 years.
  • Abbot's reportable product segments include Nutritional products, Established Pharmaceutical Products, Cardiovascular and Neuromodulation Products, and Diagnostic Products. Diabetes Care Products are considered non-reportable and are included in the 'Other' segment in the financial statements. Total international sales for the Other segment in 2018 were approximately $1.1 billion.
  • The company's diabetes management products and services include; Freestyle Libre 2, Freestyle Libre, Freestyle Optium/Precision Neo, Freestyle Freedom Lite, Freestyle Lite, Freestyle Insulinx, Freestyle Libre Pro, Freestyle LibreLink App, and LibreLinkup App for use by individuals, professionals health providers and hospitals. Moreover, they have diabetes data management services which include; Libreview, Freestyle Libre Pro Software, Freestyle Libre Software, Freestyle Auto-Assist 2.0 Software, and Freestyle Auto-Assist Neo Software.
  • Abbot's competitive advantage is and has been over the years its ability to produce very innovative proNetducts. An example is their latest innovation, the FreeStyle Libre, which enables diabetic continuous tracking of blood sugar levels without enduring the pain of being pricked, as it was done traditionally.
  • The target market for Abbot's diabetes management products include; hospitals, retailers, distributors, wholesalers, laboratories, healthcare facilities, government agencies as well as physicians' offices.

ONE DROP

RESEARCH STRATEGY

In order to comprehensively cover all the data points that show the comparison between Abbot and One Drop, we scoured the two companies' websites, market reports, Abbot annual report, and databases. We were able to find information on all the data points except for the annual revenue for the diabetes management product, focusing on the U. S geographical region.
Since One Drop is a privately-owned company, it is not obligated to publicly publish its financial records. With the lack of information on One Drop's annual revenue, we located the company's investor's funding activity from the Crunchbase database.
Abbot's 2018 annual report showed its annual financial records. However, the company stated that Diabetes Care Products are non-reportable and therefore included then in the 'Other' segment of their sales financial statement. Moreover, the given figure was for international 'other' sales and not specifically for the U. S region.
Part
08
of nine
Part
08

Diabetes Management Products Companies, Part 3

Of the three emerging diabetes management companies researched, Pops! Diabetes Care, Insulet, and Bigfoot Biomedical, all are leading the way with technologically advanced instrumentation that aim to assist diabetes patients in monitoring glucose levels, while adding additional features such as pairing them with technologies available to the public such as mobile applications. The United States and Canada lead the global market for Blood Glucose Monitoring (BGM) Devices, accounting for 36.9% market share in 2019, which is projected to reach US$8.7 billion by 2026. The attached spreadsheet will describe further indicators for these companies.

Pops! Diabetes Care

  • Founded in May 2013, Pops Diabetes Care was formed by Lonny Stormo, Dan Davis, and Curt Christensen.
  • Pops Diabetes Care provides blood glucose meters that connects "to a cellphone case and syncs with the Pops! App via Bluetooth" for diabetes management.
  • Pops Diabetes Care was selected based on its startup series A funding status in the field of diabetes management and monitoring equipment, and it is recognized by industry leaders such as the American Diabetes Association and the Federal Drug Administration.
  • Locations for Pops Diabetes Care are currently in Minneapolis, Minnesota, and Sunnyvale, California, and its products are sold throughout the United States.

Insulet

  • The Insulet Corporation is an innovative medical device company with a mission of improving the lives of people living with diabetes through their Omnipod product platform.
  • The Omnipod is a simple wearable, disposable Pod that can provide a maximum of three days of continuous insulin delivery that does not require handling a needle.
  • For the FY 2018, it earned a revenue of $564 million, which was up $100 million over the previous year, indicating an increase of 22%.
  • Insulet is one of three major competitors (Medtronic and Tandem), and is known for its OmniPod system. The OmniPod system is the top tubeless insulin pump available on the market right now. It is both waterproof and discreet when worn under clothing.
  • The Insulet Corporation is headquartered in Acton, Massachusetts, and its products are available throughout the United States.

Bigfoot Biomedical

  • Bigfoot Biomedical serves markets throughout the United States, Canada, and Mexico. Bigfoot Biomedical is headquartered in Milpitas, California.
  • Geographic coverage also includes Europe, Asia-Pacific, and South America.





Part
09
of nine
Part
09

Diabetes Management Products Companies, Part 4

Insulet earns the biggest revenue from its diabetes management products with $564 million in 2018, while Bigfoot Biomedical earned $25.6 million and Pops Diabetes made between $2 million-$5 million annually. Diabetes patients are the target market for the three companies. More information is also available in the attached spreadsheet.

Pops Diabetes

  • According to Inc., the revenue of Pops Diabetes is between $2 million-$5 million annually.
  • A list of the company's diabetes management products is the Pops! one System, Rebel (hardware), and Mina (app).
  • The competitive advantage of the company is its application of virtual care with simple consumer experience to give people who must manage a condition the freedom to oversee the management of these conditions on their terms.
  • Diabetes patients are the company's target market.

Insulet

  • The most recent revenue of the company is $564 million.
  • A list of the company's diabetes management products is Omnipod, Omnipod DASH, Omnipod Horizon, and the Omnipod Insulin Management System.
  • The competitive advantage of the company is its offering of a highly differentiated product platform that allows for "simple, tubeless, convenience, compliance, and control." Its competitive advantage also includes its operational excellence through its state-of-the-art facility and supply chain optimization.
  • Diabetes patients are the company's target market.

Bigfoot Biomedical

Research Strategy

Outside the companies' websites, SEC filings, and the annual report available for Insulet, we examined reliable news outlets and industry analysis of platforms such as Forbes, Inc., Medical Alley, Mobi Health News, and others, to determine the revenues, target market, products, and competitive advantages of these companies.

Our findings revealed that the three companies are in the business of diabetes management products ONLY, hence there was no reason to segment their revenues. For instance, the President of Insulet Corporation only mentioned products (without services) in its 2019 letter addressed to shareholders. Also, in its 2018 Investor Presentation, the company only mentioned products (without services). The same applies to the other two companies.
Sources
Sources

From Part 04
From Part 06
Quotes
  • "BD has leveraged deep expertise and advanced technologies to continuously innovate our pen needles, insulin syringes and other products. Our products are diligently designed to enable people who are living with diabetes to benefit from comfortable, effective diabetes care."
Quotes
  • "BD associates have a passion and commitment to help improve outcomes by advancing clinical therapy for patients, optimizing clinical processes for healthcare providers and enhancing safety for patients and healthcare workers."
Quotes
  • "BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. "
Quotes
  • "Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world."
From Part 08
Quotes
  • "Oak Park Heights-based Pops aims to make it easier for people with diabetes to monitor their glucose levels and better manage their health"
  • "Pops will use the new round of capital to further fund commercialization of its FDA-approved Pops-one System, which commercially launched earlier this year. Prior to this, the company had raised about $5 million, mostly from angel investors, after its launch in 2010"